Carmell Announces Closing of Elevai Skincare Acquisition

Rhea-AI Summary

Carmell (NASDAQ: CTCX) has completed its acquisition of Elevai Skincare's skin and hair care business. The purchase consideration includes approximately $1.1 million in Carmell common stock at $0.8488 per share, with 1,149,226 shares issued at closing and 117,814 shares held back for indemnification purposes. Additional terms include approximately $57,000 in cash for specified inventory and assumption of Elevai's contractual liabilities.

The deal includes earnout considerations of 5% of net sales from existing products over 5 years and a $500,000 milestone payment if hair and scalp products achieve $500,000 in revenue within 24 months. Acquired assets include Elevai's product portfolio with FY2024 revenue of approximately $2.5 million, commercial team, inventory valued at $1.0 million, and accounts receivable of $0.03 million. Post-acquisition, Carmell's total outstanding common stock is approximately 30.1 million shares.

Positive

• Acquisition of product portfolio with $2.5M annual revenue
• Significant inventory assets worth $1.0M acquired
• Expected organizational synergies and overhead cost savings
• Expansion of bio-aesthetic product portfolio and commercial footprint
• Potential for additional revenue through earnout agreement

Negative

• Immediate share dilution with issuance of 1.27M new shares
• Assumption of Elevai's contractual liabilities and trade payables
• Additional cash obligations of $57,000 for inventory

Insights

Financial Analyst

The acquisition of Elevai by Carmell represents a strategic move in the bio-aesthetics space, with a relatively modest upfront cost structure. The deal values Elevai at approximately $1.1 million in stock, plus contingent payments. The key financial metrics show Elevai generated $2.5 million in revenue for FY2024, suggesting a revenue multiple of roughly 0.44x - notably lower than industry averages for beauty and skincare acquisitions.

The deal structure is particularly favorable for Carmell, with minimal cash outlay ($57,000 for inventory) and performance-based earnouts that align with growth objectives. The 5% revenue share over 5 years and $500,000 milestone payment for hair product success create strong incentives while protecting downside risk.

The acquired $1.0 million in inventory and minimal accounts receivable ($0.03 million) suggest efficient working capital management. Post-acquisition, Carmell's share count increases to approximately 30.1 million shares, representing minimal dilution of about 4% for existing shareholders.

Market Research Analyst

This acquisition strategically positions Carmell in the rapidly growing physician-dispensed skincare market. Elevai's exosome-based products represent cutting-edge technology in the bio-aesthetics space, offering Carmell immediate entry into this premium segment. The integration brings commercial synergies through an expanded product portfolio and broader distribution network in the physician channel.

The deal's structure incentivizes future growth while minimizing upfront risk. The earnout provisions, particularly the hair product milestone, indicate Carmell's confidence in the market potential of Elevai's pipeline. With $2.5 million in existing revenue, there's significant room for expansion through cross-selling and leveraging Carmell's infrastructure.

The overhead rationalization mentioned by management suggests potential EBITDA improvements through cost synergies. This acquisition transforms Carmell from a development-stage company into a commercial entity with immediate revenue generation, potentially accelerating its path to profitability.

PITTSBURGH, Jan. 16, 2025 (GLOBE NEWSWIRE) -- Carmell Corporation (Nasdaq: CTCX), a bio-aesthetics company focused on skin and hair health (“Carmell”, the “Company”, “we”, “our”, or “us”), today announced the closing of the previously announced acquisition of the skin and hair care business of Elevai Skincare, Inc. (“Elevai”), a leader in physician dispensed exosome skin and hair care products, pursuant to a definitive purchase agreement with PMGC Holdings Inc. (formerly Elevai Labs Inc.) (“PMGC”) and Elevai, its wholly owned subsidiary (the “Acquisition”).

At the closing of the Acquisition (the “Closing”), the purchase consideration consisted of the following:

• Approximately $1.1 million of Carmell common stock at a price of $0.8488 per share as follows:
  • 1,149,226 shares of Carmell common stock at Closing, plus;
  • 117,814 shares of Carmell common stock held back by Carmell to secure indemnification obligations of PMGC and Elevai for 12 months after Closing;
• Approximately $57,000 in cash to be paid by Carmell upon the sale of specified inventory existing as of the Closing; and
• Carmell’s assumption of contractual liabilities and trade payables of Elevai at the Closing.
  

Additional post-Closing earnout consideration of:

• 5% of net sales from Elevai’s existing products paid annually during the 5-year period following the Closing, and
• One-time milestone payment of $500,000 if Elevai’s hair and scalp products achieve $500,000 in net revenue within 24 months following the Closing.

As part of the Acquisition, Carmell acquired the following assets of Elevai:

• Product portfolio with FY2024 revenue of approximately $2.5 million;
• Commercial and product development team;
• Finished and work-in-process inventory of approximately $1.0 million; and
• Accounts receivable of approximately $0.03 million.

Said Mr. Rajiv Shukla, Chairman of Carmell, “Carmell expects to achieve significant benefits from organizational synergies and savings from overhead rationalization. This transaction positively impacts us in 3 key areas: (1) expands our bio-aesthetic product portfolio, (2) broadens our commercial footprint, (3) improves our cash flow.”

Following the Closing, the total number of Carmell common stock outstanding was approximately 30.1 million, not including approximately 0.12 million shares held back to secure indemnification obligations.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy any of the securities described herein, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Elevai:
A wholly-owned subsidiary of PMGC, Elevai is developing and commercializing cutting-edge physician-dispensed skin and hair care applications that focus on science-backed applications for the physician-dispensed market, utilizing cutting-edge technologies to redefine skincare and hair care, including its stem cell exosome technology.

About Carmell:
Carmell is a bio-aesthetics company that utilizes the Carmell Secretome™ to support skin and hair health. The Carmell Secretome™ consists of a potent cocktail of growth factors and proteins extracted from allogeneic human platelets sourced from U.S. Food and Drug Administration-approved tissue banks. Over the past 7 years, the Company has extensively tested the technology underpinning the Carmell Secretome™. Additionally, the Company has developed a novel microemulsion formulation that enables the delivery of lipophilic and hydrophilic ingredients without relying on the Foul Fourteen™, 14 potentially harmful excipients that are commonly used by other companies to impart texture, stability, and other desirable physicochemical attributes to cosmetic products. Carmell’s microemulsion formulations do not utilize mineral or vegetable oils and are designed to be non-comedogenic. The Company is also developing a line of men’s products and a line of topical haircare products. All products are tailored to meet the demanding technical requirements of professional care providers and discerning retail consumers. For more information, visit www.carmellcosmetics.com.

Forward-Looking Statements:
This press release contains forward-looking statements that are based on beliefs, assumptions and information currently available. In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “continue,” “ongoing” or the negative of these terms or other comparable terminology. However, not all forward-looking statements contain these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding our ability to integrate Elevai’s business, our ability to realize the anticipated benefits of the Acquisition, the impact of the Acquisition on our business, the launch and commercialization of our products, and the execution of our business strategy. We cannot assure you that the forward-looking statements in this press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties that could cause actual results to differ materially from expected results, including, among others, risks related to the ability to realize the anticipated benefits of the Acquisition, risks related to the diversion of management’s attention from our ongoing business, the risk of unknown liabilities arising after the Acquisition, the ability to recognize anticipated benefits from our commercial products, R&D pipeline, distribution agreements, changes in applicable laws or regulations, the possibility that we may be adversely affected by other economic, business, and/or competitive factors, and other risks and uncertainties, those described under the header “Risk Factors” in the Annual Report on Form 10-K filed by Carmell with the SEC on April 1, 2024, and in our other reports filed with the SEC. Most of these factors are outside of Carmell’s control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material. In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame or at all. Except as required by law, we undertake no obligation to publicly update any forward-looking statement contained herein to reflect events or circumstances after the date hereof or to reflect the occurrence of unanticipated events. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release.

Contact:
Bryan Cassaday
bc@carmellcorp.com

FAQ

What is the total value of Carmell's (CTCX) acquisition of Elevai Skincare?

The acquisition includes approximately $1.1 million in Carmell common stock, $57,000 in cash for inventory, plus earnout considerations and assumption of liabilities.

How many new shares did Carmell (CTCX) issue for the Elevai acquisition?

Carmell issued 1,149,226 shares at closing, plus 117,814 shares held back for indemnification, totaling approximately 1.27 million shares.

What are the earnout terms in Carmell's (CTCX) Elevai acquisition?

The earnout includes 5% of net sales from existing products for 5 years, plus a $500,000 milestone payment if hair/scalp products achieve $500,000 in revenue within 24 months.

What is the annual revenue of Elevai's product portfolio acquired by Carmell (CTCX)?

The acquired product portfolio has FY2024 revenue of approximately $2.5 million.

How many total shares of Carmell (CTCX) are outstanding after the Elevai acquisition?

Following the acquisition, approximately 30.1 million shares of Carmell common stock are outstanding, not including the 0.12 million shares held back.